Softwr

Healthcare · head to head

Ambra Health vs Paige

Ambra Health logo

Ambra Health

Healthcare

Cloud medical image exchange and vendor neutral archive, now part of Intelerad

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Ambra Health intelerad now owns Ambra and ambrahealth.com redirects to Intelerad client support, so a buyer is committing to the Intelerad portfolio roadmap and should get written positioning on Ambra versus Intelerad own cloud PACS before signing.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Ambra Health covers Image exchange, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Ambra Health and Paige actually diverge.

Attributes where Ambra Health and Paige differ
AttributeAmbra HealthPaige
PlatformsWeb, iOS, AndroidWeb, Cloud, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Ambra Health

  • Image exchange
  • Cloud VNA
  • Zero footprint viewer
  • Patient upload portal
  • Identity reconciliation
  • Clinical trials workflow
  • API and HL7 integration

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Ambra Health

  • A trauma centre that receives transfers from regional hospitals and needs outside CT studies readable before the patient arrives, not after a disc is walked innot Paige
  • An oncology programme collecting outside imaging for multidisciplinary tumour board review from dozens of referring practicesnot Paige
  • A clinical research organisation routing de identified trial imaging from many sites to one central reading facilitynot Paige
  • A health system trying to eliminate the CD import desk by giving patients and referring practices a direct upload portalnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Ambra Health
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Ambra Health
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Ambra Health
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Ambra Health

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Ambra Health

  • Intelerad now owns Ambra and ambrahealth.com redirects to Intelerad client support, so a buyer is committing to the Intelerad portfolio roadmap and should get written positioning on Ambra versus Intelerad own cloud PACS before signing.
  • Ambra is built for cross organisation exchange, not for high volume in department diagnostic reading, so a radiology group that expects it to replace a departmental PACS finds the reading ergonomics and hanging protocols thinner than a dedicated PACS client.
  • Pricing scales with study volume and stored capacity, so a health system that turns on patient upload broadly sees storage grow from low value outside studies it never intended to retain, and the renewal reflects that.
  • Identity reconciliation of studies arriving with foreign patient identifiers still needs human review at volume, and sites that budget for zero touch matching end up staffing an imaging records queue.
  • Adoption depends on referring practices actually using the portal, and the vendor cannot make that happen, so image exchange projects frequently stall at the outreach and change management step rather than at the technology.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Ambra Health

On request
  • Ambra Health$undefined/year
    • Priced by annual study volume and stored capacity
    • Exchange partner connections and upload portals scoped per deployment
    • Zero footprint viewer licensed with the platform

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Ambra Health if

  • You need image exchange.
  • You work on Web, iOS, Android.
  • You also want cloud vna.
Ambra Health review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Ambra Health or Paige better?
Neither clearly leads. Ambra Health starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Ambra Health or Paige?
Ambra Health starts at On request and Paige at On request.
Does Ambra Health or Paige run on more platforms?
Ambra Health runs on Web, iOS, Android. Paige runs on Web, Cloud, On-premise.
What is Ambra Health best used for?
Ambra Health is most often used for a trauma centre that receives transfers from regional hospitals and needs outside ct studies readable before the patient arrives, not after a disc is walked in, an oncology programme collecting outside imaging for multidisciplinary tumour board review from dozens of referring practices, a clinical research organisation routing de identified trial imaging from many sites to one central reading facility, a health system trying to eliminate the cd import desk by giving patients and referring practices a direct upload portal. Of those, a trauma centre that receives transfers from regional hospitals and needs outside ct studies readable before the patient arrives, not after a disc is walked in and an oncology programme collecting outside imaging for multidisciplinary tumour board review from dozens of referring practices are not what Paige is typically brought in for.
What can Ambra Health do that Paige cannot?
Ambra Health covers Image exchange, Cloud VNA, Zero footprint viewer, Patient upload portal. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Ambra Health: Is Ambra Health still sold under its own name?

Yes. Intelerad still markets Ambra Health as a named product line, but the standalone website redirects to Intelerad, and support and contracting run through Intelerad.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Ambra Health: Can Ambra replace our PACS?

For image exchange, archiving and clinical viewing, yes. For high volume diagnostic radiology reading it is generally deployed alongside a departmental PACS rather than instead of one.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Ambra Health: Is pricing published?

No. It is quoted by annual study volume, stored capacity and the scope of exchange connections.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Ambra Health: Does the viewer require software on referring physician machines?

No. The viewer is zero footprint HTML5, which is the main reason referring practices adopt it at all.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Ambra Health

More on Paige

Keep looking

Other head to heads